330 related articles for article (PubMed ID: 21842339)
1. Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.
Tomasi G; Turkheimer F; Aboagye E
Mol Imaging Biol; 2012 Apr; 14(2):131-46. PubMed ID: 21842339
[TBL] [Abstract][Full Text] [Related]
2. [Molecular imaging with new PET tracers].
Beer AJ; Schwaiger M
Radiologe; 2007 Jan; 47(1):8-17. PubMed ID: 17136403
[TBL] [Abstract][Full Text] [Related]
3. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
4. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
5. Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging.
Schiepers C; Dahlbom M
Eur Radiol; 2011 Mar; 21(3):548-54. PubMed ID: 21174096
[TBL] [Abstract][Full Text] [Related]
6. Quantitative PET in the 2020s: a roadmap.
Meikle SR; Sossi V; Roncali E; Cherry SR; Banati R; Mankoff D; Jones T; James M; Sutcliffe J; Ouyang J; Petibon Y; Ma C; El Fakhri G; Surti S; Karp JS; Badawi RD; Yamaya T; Akamatsu G; Schramm G; Rezaei A; Nuyts J; Fulton R; Kyme A; Lois C; Sari H; Price J; Boellaard R; Jeraj R; Bailey DL; Eslick E; Willowson KP; Dutta J
Phys Med Biol; 2021 Mar; 66(6):06RM01. PubMed ID: 33339012
[TBL] [Abstract][Full Text] [Related]
7. Present role and future prospects of positron emission tomography in clinical oncology.
Oriuchi N; Higuchi T; Ishikita T; Miyakubo M; Hanaoka H; Iida Y; Endo K
Cancer Sci; 2006 Dec; 97(12):1291-7. PubMed ID: 17052261
[TBL] [Abstract][Full Text] [Related]
8. [Positron-emission tomography in urooncology].
Maurer T; Kübler H; Gschwend JE; Eiber M
Urologe A; 2015 Jul; 54(7):983-91. PubMed ID: 26109122
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of FDG PET.
Hoh CK
Nucl Med Biol; 2007 Oct; 34(7):737-42. PubMed ID: 17921026
[TBL] [Abstract][Full Text] [Related]
10. Effect of hyperglycemia on brain and liver
Viglianti BL; Wong KK; Wimer SM; Parameswaran A; Nan B; Ky C; Townsend DM; Rubello D; Frey KA; Gross MD
Biomed Pharmacother; 2017 Apr; 88():1038-1045. PubMed ID: 28192877
[TBL] [Abstract][Full Text] [Related]
11. The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective.
Lucignani G; Paganelli G; Bombardieri E
Nucl Med Commun; 2004 Jul; 25(7):651-6. PubMed ID: 15208491
[TBL] [Abstract][Full Text] [Related]
12. Utility of 18F-FDG PET in evaluating cancers of lung.
Acker MR; Burrell SC
J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
[TBL] [Abstract][Full Text] [Related]
13. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
[TBL] [Abstract][Full Text] [Related]
14. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT).
Mehta NN; Torigian DA; Gelfand JM; Saboury B; Alavi A
J Vis Exp; 2012 May; (63):e3777. PubMed ID: 22588186
[TBL] [Abstract][Full Text] [Related]
15. PET imaging: implications for the future of therapy monitoring with PET/CT in oncology.
Tomasi G; Rosso L
Curr Opin Pharmacol; 2012 Oct; 12(5):569-75. PubMed ID: 22901680
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology.
Shields AF
Mol Imaging Biol; 2006; 8(3):141-50. PubMed ID: 16534552
[TBL] [Abstract][Full Text] [Related]
17. Tumor quantification in clinical positron emission tomography.
Bai B; Bading J; Conti PS
Theranostics; 2013 Oct; 3(10):787-801. PubMed ID: 24312151
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies.
van Velden FH; Cheebsumon P; Yaqub M; Smit EF; Hoekstra OS; Lammertsma AA; Boellaard R
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1636-47. PubMed ID: 21617975
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
20. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
